journal
MENU ▼
Read by QxMD icon Read
search

Immunology and Allergy Clinics of North America

journal
https://www.readbyqxmd.com/read/28366489/biologic-therapies-of-immunologic-diseases
#1
EDITORIAL
Bradley E Chipps, Stephen P Peters
No abstract text is available yet for this article.
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366488/biopharmaceuticals-in-allergic-disease-finding-the-right-patients-at-the-right-time
#2
EDITORIAL
Stephen A Tilles
No abstract text is available yet for this article.
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366487/erratum
#3
(no author information available yet)
No abstract text is available yet for this article.
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366486/future-prospects-of-biologic-therapies-for-immunologic-diseases
#4
REVIEW
Santhosh Kumar, Brant R Ward, Anne-Marie Irani
This article presents an overview of future uses for biologic therapies in the treatment of immunologic and allergic conditions. Discussion is centered on the use of existing therapies outside of their current indication or on new therapies that are close to approval. This information may help familiarize practicing allergists and immunologists with therapies they may soon encounter in their practice as well as help identify conditions and treatments that will require further study in the near future.
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366485/pharmacoeconomics-of-biologic-therapy
#5
REVIEW
Don A Bukstein, Allan T Luskin
Novel biologic agents have allowed clinicians to achieve improved patient outcomes. Appropriate pharmacoceconomic analyses demand evaluation of all relevant costs, including the treatments, the disease and comorbidities, and costs of alternative treatments, including their short- and long-term side effects. Only with complete data can the value of therapies be correctly estimated. By assessing costs, pharmacoeconomic studies complement studies of efficacy and safety, helping to determine the relationships of treatment and outcome...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366484/adverse-reactions-to-biologic-therapy
#6
REVIEW
Sheenal V Patel, David A Khan
Biologic therapies are emerging as a significant therapeutic option for many with debilitating inflammatory and autoimmune conditions. As expansion in the number of FDA-approved agents continue to be seen, more unanticipated adverse reactions are likely to occur. Currently, the diagnostic tools, including skin testing and in vitro testing, to evaluate for immediate hypersensitivity reactions are insufficient. In this review, management strategies for common acute infusion reactions, injection site reactions, and immediate reactions suggestive of IgE-mediated mechanisms are discussed...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366483/biologic-therapies-for%C3%A2-immunoglobulin-e-mediated-food-allergy-and-eosinophilic-esophagitis
#7
REVIEW
Iris M Otani, Kari C Nadeau
Immunoglobulin (Ig) E-mediated food allergy and eosinophilic esophagitis (EoE) are chronic, allergen-mediated disorders characterized by an aberrant TH2 immune response. The development and investigation of biologics for the treatment of IgE-mediated food allergy and eosinophilic esophagitis have provided further insight into the pathophysiology and management of these disorders. This article provides an overview of biologic therapies that are being investigated or have potential as treatments for IgE-mediated food allergy and eosinophilic esophagitis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366482/monoclonal-antibodies-for-the-treatment-of-nasal-polyps
#8
REVIEW
Thomas J Willson, Robert M Naclerio, Stella E Lee
Biologics are novel therapeutic medications developed for the targeted therapy for a variety of inflammatory conditions. The biologics currently investigated for the treatment of chronic rhinosinusitis (CRS) with nasal polyps modulate specific inflammatory pathways involved in the pathogenesis of disease. Investigations have focused on the most severe form of the disease, namely, CRS with nasal polyps. It is hoped that specific targeted therapies using these biologics can significantly modulate the immune system, offering both disease control and symptomatic relief...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366481/biologic-therapy-in-chronic-obstructive-pulmonary-disease
#9
REVIEW
Julia W Tripple, Jennifer L McCracken, William J Calhoun
Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366480/biologic-and-new-therapies-in-asthma
#10
REVIEW
Farnaz Tabatabaian, Dennis K Ledford, Thomas B Casale
Several biologics are currently FDA approved for asthma that target Th2 high patients. Unfortunately, 50% of patients with severe asthma do not fit this phenotype of disease and have fewer effective therapeutic options. In the clinical setting, total IgE, FeNO and peripheral blood eosinophils are important tools in defining Th2 high patients with asthma. However, precise biomarkers to predict better response to one specific Th2 high asthma therapy versus another is lacking. It is important to recognize that none of the current medications targeting the Th2 pathway induces persistent immunomodulation or remission...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366479/biologic-therapy-in-the-treatment-of-chronic-skin-disorders
#11
REVIEW
James M Fernandez, Anthony P Fernandez, David M Lang
Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366478/immune-mechanisms-and-novel-targets-in-rheumatoid-arthritis
#12
REVIEW
Swamy Venuturupalli
Significant progress has been made in understanding the pathophysiology of rheumatoid arthritis. It is widely recognized that early institution of treatment is one of the best predictive factors for response to therapy. Several novel approaches are currently being investigated and several novel biologics are in various stages of development. With advances in the fields of proteomics, genomics, and metabolomics, specific phenotypes of the disease can be better identified and specific therapies for particular phases of the disease and specific patients will allow for improved control of this condition...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366477/biologic-therapies-for-autoimmune-and-connective-tissue-diseases
#13
REVIEW
Rachel M Wolfe, Dennis C Ang
Biologic therapy continues to revolutionize the treatment of autoimmune disease, especially in rheumatology as the pathophysiology of both inflammation and autoimmune disease becomes better understood. These therapies are designed to dampen the response of the inflammatory cascades. Although the first biologic therapies were approved many years ago, expanding indications and new agents continue to challenge the traditional treatment strategies for rheumatic diseases. This article reviews the data supporting the current use of biologic therapies, including off-label indications, in a subset of rheumatic diseases including rheumatoid arthritis, lupus, inflammatory myositis, ankylosing spondylitis, psoriatic arthritis, vasculitis, and gout...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366476/patient-characteristics-and-individualization-of-biologic-therapy
#14
REVIEW
Steven Draikiwicz, John Oppenheimer
Progress in the understanding of disease processes has provided additional therapeutic targets, best exemplified by the increasing role of biologics in the clinical armamentarium. This article provides a focused review of current treatment paradigms and pathophysiology for asthma, atopic dermatitis, urticaria, as well as C1 inhibitor deficiency. It elucidates the populations in which biologics were studied for the aforementioned disease states, emphasizing characteristics to consider when selecting therapy...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366475/biological-therapies-of-immunologic-diseases-strategies-for-immunologic-interventions
#15
REVIEW
Brooke I Polk, Lanny J Rosenwasser
The immune system possesses a vast number of potential targets for therapeutic intervention. Although therapies for many pathways have been pursued, only few have yielded significant success. Hindrances in altering biologic pathways include the potential for unwanted downstream effects, ineffectiveness owing to biological redundancy, recognition of a therapeutic molecule as foreign by the body's innate immune system, and the risks of subsequent malignancy and/or autoimmunity. This article covers currently available biotherapeutic agent classes as well as potential direction for future therapy...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28366474/inflammatory-disorders-associated-with-allergy-overview-of-immunopathogenesis-and-implications-for-treatment
#16
REVIEW
Jonathan Corren
A number of chronic inflammatory diseases are associated with IgE-mediated immunologic hypersensitivity, including atopic dermatitis, chronic rhinosinusitis, and asthma. Pathogenetic studies of well-characterized patient groups has allowed investigators to more precisely define the molecular pathways involved in these diseases. Specific cytokines and chemokines, as well as other unique proteins, have now been identified in each of these common disorders and a number of medications are currently in development for inhibiting their actions...
May 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27886915/allergic-skin-diseases
#17
EDITORIAL
Peck Y Ong, Peter Schmid-Grendelmeier
No abstract text is available yet for this article.
February 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27886914/allergic-skin-disease-and-the-practicing-allergist-growing-unmet-need-new-science-and-new-treatments
#18
EDITORIAL
Stephen A Tilles
No abstract text is available yet for this article.
February 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27886913/biologics-in-chronic-urticaria
#19
REVIEW
Adeeb Bulkhi, Andrew J Cooke, Thomas B Casale
Chronic urticaria (CU) is defined as wheals, angioedema, or both, that last more than 6 weeks. Second-generation antihistamines are considered the first-line therapy for CU. Unfortunately, many patients will fail antihistamines and require alternative therapy, including immune response modifiers or biologics. Multiple biological agents have been evaluated for use in antihistamine-refractory CU, including omalizumab, rituximab, and intravenous immunoglobulin; omalizumab is the most efficacious. Because of the success of omalizumab, multiple new biologics that are directed at the IgE pathway are under investigation...
February 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/27886912/infectious-complications-in-atopic-dermatitis
#20
REVIEW
Di Sun, Peck Y Ong
Atopic dermatitis is characterized by the interplay of skin barrier defects with the immune system and skin microbiome that causes patients to be at risk for infectious complications. This article reviews the pathogenesis of atopic dermatitis and the mechanisms through which patients are at risk for infection from bacterial, viral, and fungal pathogens. Although these complications may be managed acutely, prevention of secondary infections depends on a multipronged approach in the maintenance of skin integrity, control of flares, and microbial pathogens...
February 2017: Immunology and Allergy Clinics of North America
journal
journal
29830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"